Cargando…
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066856/ https://www.ncbi.nlm.nih.gov/pubmed/27784993 http://dx.doi.org/10.2147/DDDT.S85050 |